1-9 of 9
Matthew Frigault
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Clinical Trials & Observations
Magdi Elsallab, Moataz Ellithi, Matthew A. Lunning, Christopher D’Angelo, Jihyun Ma, Miguel-Angel Perales, Matthew Frigault, Marcela V. Maus
Journal: Blood
Blood (2024) 143 (20): 2099–2105.
https://doi.org/10.1182/blood.2024024166
Published: 2024
Includes: Supplemental data
Journal Articles

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle
Journal: Blood
Blood (2022) 140 (Supplement 1): 1584–1587.
https://doi.org/10.1182/blood-2022-158822
Published: 2022
Journal Articles

YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

Pere Barba, Mi Kwon, Javier Briones, Ulrich Jaeger, Emmanuel Bachy, Didier Blaise, Nicolas Boissel, Koji Kato, Nirav N. Shah, Matthew Frigault, Peter A. Riedell, Leyla O. Shune, Takanori Teshima, Fabio Ciceri, David Pearson, Elena J Orlando, Lan Yi, Jaclyn Davis, Aisha Masood, Ian W. Flinn, Michael Dickinson
Journal: Blood
Blood (2022) 140 (Supplement 1): 1056–1059.
https://doi.org/10.1182/blood-2022-162520
Published: 2022
Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Matthew Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Christine Cornwell, Kamalika Banerjee, Anand Rotte, Christopher R. Heery, David Avigan, Andrzej Jakubowiak, Michael R. Bishop
Journal: Blood
Blood (2022) 140 (Supplement 1): 7439–7440.
https://doi.org/10.1182/blood-2022-163827
Published: 2022
Journal Articles

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Patrick Connor Johnson, Tejaswini Dhawale, Mitchell W. Lavoie, Kyle Karpinski, Netana H. Markovitz, Kathleen Hennessey, Matthew Frigault, Areej El-Jawahri
Journal: Blood
Blood (2022) 140 (Supplement 1): 5232–5233.
https://doi.org/10.1182/blood-2022-163194
Published: 2022
Journal Articles

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Tejaswini Dhawale, P. Connor Johnson, Mahmoud R. Gaballa, Ashley Nelson, Mitchell W. Lavoie, Matthew Frigault, Kofi Boateng, Claire Greydanus, Areej El-Jawahri
Journal: Blood
Blood (2022) 140 (Supplement 1): 10989–10990.
https://doi.org/10.1182/blood-2022-162494
Published: 2022
Journal Articles

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael Pratta, Lea Burke, John F. DiPersio, Richard T. Maziarz, Patricia Feldman, Teresa Brodeur, Cynthia Timmers, Olga Ivanova, April Barbour, Rodica Morariu-Zamfir, Matthew Frigault
Journal: Blood
Blood (2022) 140 (Supplement 1): 10350–10351.
https://doi.org/10.1182/blood-2022-169382
Published: 2022
Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2199.
https://doi.org/10.1182/blood-2019-131533
Published: 2019
Journal Articles

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Irene Scarfò, PhD, Kathleen Gallagher, Marcela V. Maus, MD PhD, Rebecca Larson, BS, Maegan Sheehan, BS, Gabrielle Brini, MSc, Scott Bornheimer, Mary Beth Hanley, Matthew Frigault, MD MSc, Mark Leick, MD, Alena Chekmasova, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5626.
https://doi.org/10.1182/blood-2019-128745
Published: 2019